GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
Metastatic Gastric Cancer
DRUG: durvalumab, tremelimumab, paclitaxel
Safety based on NCI-CTCAE v4.03, Safety will be assessed in all patients who received at least one dose of study drugs based on NCI-CTCAE v4.03, at least 4 weeks|response rate, Response rate will be assessed by a team of independent reviewers based on RECIST v1.1., up to 12 months
To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy